{"slideshow_credits": null, "snippet": "The company is said to be teaming up with shareholders including Pershing Square Capital Management to bring its offer above $160 a share.", "abstract": "Valeant Pharmaceuticals intends to work with Pershing Square Capital Management and top shareholders to raise bid for Salix Pharmaceuticals to above $160 per share in cash.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "David", "role": "reported", "lastname": "GELLES", "rank": 1, "organization": ""}], "original": "By DAVID GELLES"}, "web_url": "http://www.nytimes.com/2015/03/14/business/dealbook/valeant-said-to-be-planning-to-raise-its-bid-for-salix-pharmaceuticals.html", "lead_paragraph": "The company is said to be teaming up with shareholders including Pershing Square Capital Management to bring its offer above $160 a share.", "headline": {"main": "Valeant Said to Be Planning to Raise Its Bid for Salix Pharmaceuticals", "print_headline": "Business Briefing; Valeant Prepares New Salvo in War for Drug Maker"}, "_id": "55031f6138f0d835da194e6d", "word_count": "720", "multimedia": [{"height": 126, "url": "images/2015/03/13/business/dealbook/dbpix-valeant/dbpix-valeant-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/03/13/business/dealbook/dbpix-valeant/dbpix-valeant-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/03/13/business/dealbook/dbpix-valeant/dbpix-valeant-articleLarge.jpg", "legacy": {"xlarge": "images/2015/03/13/business/dealbook/dbpix-valeant/dbpix-valeant-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/03/13/business/dealbook/dbpix-valeant/dbpix-valeant-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/03/13/business/dealbook/dbpix-valeant/dbpix-valeant-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-03-14T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y", "rank": "1"}, {"name": "persons", "value": "Ackman, William A", "is_major": "N", "rank": "11"}, {"name": "persons", "value": "Pearson, John Michael (1959- )", "is_major": "N", "rank": "12"}, {"name": "organizations", "value": "Pershing Square Capital Management", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Salix Pharmaceuticals Ltd", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Hedge Funds", "is_major": "N", "rank": "6"}, {"name": "organizations", "value": "Actavis PLC", "is_major": "N", "rank": "7"}, {"name": "organizations", "value": "Allergan Inc", "is_major": "N", "rank": "8"}, {"name": "organizations", "value": "Endo International PLC", "is_major": "N", "rank": "9"}, {"name": "organizations", "value": "ValueAct Capital Partners", "is_major": "N", "rank": "10"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}